Psyence BioMed Welcomes U.S. Executive Action to Advance Ibogaine Research

Psyence BioMed has welcomed a new U.S. executive action designed to facilitate and accelerate scientific research into ibogaine. The government initiative aims to explore the therapeutic potential of this psychedelic compound while establishing a regulated and ethically sourced supply for medical studies. In response, the company highlighted its global leadership in manufacturing GMP-compliant ibogaine, positioning itself as a key player in the specialized supply chain. This executive move provides a significant regulatory tailwind for biotech firms focused on psychedelic medicine. Analysts suggest that the action could increase market demand for Psyence BioMed’s certified products and bolster its overall valuation. The development marks a pivotal step in the integration of psychedelic compounds into mainstream pharmaceutical research.